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Abstract: In vitro selected ribozymes are promising tools for
site-specific labeling of RNA. Previously known nucleic acid
catalysts attached fluorescently labeled adenosine or guanosine
derivatives through 2’,5’-branched phosphodiester bonds to the
RNA of interest. Herein, we report new ribozymes that use
orthogonal substrates, derived from the antiviral drug tenofo-
vir, and attach bioorthogonal functional groups, as well as
affinity handles and fluorescent reporter units through a hydro-
lytically more stable phosphonate ester linkage. The tenofovir
transferase ribozymes were identified by in vitro selection and
are orthogonal to nucleotide transferase ribozymes. As genet-
ically encodable functional RNAs, these ribozymes may be
developed for potential cellular applications. The orthogonal
ribozymes addressed desired target sites in large RNAs in vitro,
as shown by fluorescent labeling of E. coli 16S and 23S rRNAs
in total cellular RNA.
Site-specific labeling of RNA by covalent attachment of
a bioorthogonal functional group or fluorescent reporter is of
fundamental importance for biochemical and biophysical
studies and in the areas of cellular and synthetic biology.[1]
Non-covalent labeling of RNA has been pursued by fluo-
rogen-activating aptamers that are inserted into the RNA of
interest as large fluorescent tags.[2] Covalent labeling with
small organic fluorophores through bioorthogonal linkages
has several advantages. While incorporation of modified
nucleotides by solid-phase synthesis is limited to short RNAs,
several strategies are known to post-synthetically address
natural RNAs at terminal or internal positions.[3] Selected
examples include ribozymes for 3’-terminal labeling,[4] protein
enzymes for labeling of the cap structure,[5] and RNA–protein
complexes to address specific nucleotides in a defined
sequence context.[6]
Nucleic acid catalysts, that is, ribozymes and deoxyribo-
zymes can be engineered for any particular sequence and
have successfully been used to address internal target sites for
various in vitro applications.[7] Recently, we reported the
FH14 ribozyme to attach N6-labeled adenosine to specific
internal 2’-OH groups through 2’,5’-phosphodiester bonds.[8]
This ribozyme was identified by direct in vitro selection with
N6-modified ATP as substrate and a structured RNA library
with a bulged adenosine as target site for labeling. The
resulting ribozymes proved specific, efficient and generally
applicable even in the context of cellular RNA. However,
several difficulties arise when FH14 and related ribozymes
are considered for potential future cellular applications. N6-
modified ATP analogues would compete with cellular ATP
and ATP-dependent enzymatic processes, and result in
ribozyme-independent background labeling of RNA by
polymerase incorporation.[9] Moreover, the resulting 2’,5’-
phosphodiester linkage in the labeled RNA is easily cleaved
by natural debranching enzymes.[10] We sought to address
these issues of lacking orthogonality and vulnerability to
debranching enzymes by attachment of non-natural nucleo-
tide analogues. Specifically, we considered tenofovir diphos-
phate as a ribozyme substrate. Tenofovir is an FDA-approved
acyclic nucleotide phosphonate that is used as an antiviral
drug against human immunodeficiency virus (HIV) and
hepatitis B virus (HBV) infections.[11] It is administered as
a lipophilic cell-permeable prodrug, in which the negatively
charged phosphonate is masked as an isopropyl methyl
carbonate ester (tenofovir disoproxil fumarate, TDF),[12] or
phosphonamidate (tenofovir alafenamide, TAF).[13] Upon
release by esterases, tenofovir is phosphorylated by cellular
nucleotide kinases to tenofovir diphosphate, which is the
active drug metabolite that acts as an obligatory chain-
terminator of viral polymerases such as retroviral reverse
transcriptase.[14] Tenofovir exhibits low cytotoxicity, is a poor
substrate for mammalian polymerases,[15] and would also be
much less efficiently incorporated into RNA compared to
ATP analogues. Ribozyme-catalyzed ligation of tenofovir-
diphosphate to an internal 2’-OH of any RNA of interest
would result in a branched phosphonate ester linkage
(Figure 1), which is expected to be more resistant against
enzymatic hydrolysis (debranching) compared to a natural
phosphodiester linkage. Tenofovir analogues could be
equipped with bioorthogonal handles or fluorescent report-
ers, and thus represent attractive substrates for ribozyme-
catalyzed RNA labeling and visualization.
The previously identified adenylyl-transferase ribozyme
FH14[8] was tested with tenofovir diphosphate, but it was not
able to use the acyclic adenosine derivative as a substrate for
RNA labeling (Figure S1). Therefore, we used in vitro
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selection from a structured RNA pool containing 40 random
nucleotides to identify new ribozymes for site-specific label-
ing of RNA with bioorthogonal derivatives of antiviral
nucleoside analogues (the in vitro selection scheme is shown
in the Supporting Information, Figure S2). We found several
tenofovir-transferase ribozymes (TTRs) that form a phospho-
nate ester with the 2’-OH of the target adenosine using N6-
modified tenofovir diphosphate as substrate (Figure 1).
Using Watson–Crick base-paired binding arms, the ribo-
zymes target a bulged adenosine in the RNA of interest and
catalyze labeling of its 2’-OH group. A biotinylated tenofovir
substrate was used for a bead-based in vitro selection strategy
through streptavidin-coated magnetic beads, in analogy to the
previously established procedure (with N6-biotin-ATP that
resulted in FH ribozymes).[8] The N6-biotinylated tenofovir
diphosphate (biotin-Ten-DP) was synthesized from 6-chloro-
purine in 7 steps (Scheme S1), in analogy to other N6-
substituted [N-(2-phosphonomethoxy)alkyl adenines,[16] and
was used at a concentration of 200 mm with 20 mm Mg2+ at
pH 7.4. The RNA library was partially labeled with Lucifer
yellow at its 3’-terminal ribose, and the progress of the in vitro
selection was monitored by measuring fluorescence of eluted
RNA after each selection round (Figure 2a). The incubation
time was gradually reduced after round 7 to enrich faster
ribozymes. The pool was subjected to cloning after 12 rounds
of selection, and Sanger sequencing identified two ribozymes,
named FJ1 and FJ8. In addition, the round 7 and round 12
pools were analyzed by Illumina sequencing.[17] Comparison
of resulting sequence families (Figure 2b and Figure S3)
showed that FJ1 and FJ8 families were most enriched (with
log2 ratios of 8.7 and 9.7, respectively), and FJC9 was
identified as an additional unrelated ribozyme candidate
(log2 ratio of 4.3) that proved worthwhile of more detailed
investigation.[18] FJ1 and FJ8 share some sequence segments
(Figure 2c), although their predicted secondary structures are
quite different (Figure S4).
All three ribozymes FJ1, FJ8, and FJC9 showed high trans
activity (Figure 2d), yielding circa 80% biotin-tenofovir-
labeled RNA after overnight incubation. The phosphonate
ester linkage in the FJ1-labeled RNA product was confirmed
by mass spectrometry (Figure S5), and the labeling site at the
expected 2’-OH of A10 was revealed by the gel shift of the
RNase T1 digestion products and alkaline hydrolysis products
(Figure 3a and Figure S6). Moreover, upon incubation with
yeast debranching enzyme Dbr1, the phosphonate linkage in
the FJ1 product was significantly more stable compared to the
phosphodiester produced by the FH14 ribozyme with N6-
biotin ATP. Under the in vitro conditions with highly active
Figure 1. Ribozyme-catalyzed site-specific labeling of an RNA target
using N6-biotinylated tenofovir diphosphate (biotin-Ten-DP), forming
a phosphonate ester linkage with the 2’-OH of the bulged adenosine
(red) that is located in between two Watson–Crick base-paired regions
with the ribozyme’s binding arms (grey). The RNA target sequence
used for in vitro selection was 5’-GGACAUACUGAGCCUUCAA.
Figure 2. a) Progress of in vitro selection monitored by fluorescence of
eluted fraction. Round 7 and round 12 libraries were analyzed by
sequencing. b) Abundance of individual sequences in reads per million
(RPM) compared in R7 and R12. Sequence clusters with Levenshtein
edit distance <4 are indicated in same color. See detailed legend in
Figure S3. c) Sequences of ribozymes FJ1, FJ8, and FJC9 (manually
aligned). d) Trans activity assay with biotin-Ten-DP and 3’-fluorescein-
labeled 19-nt RNA substrate GGACAUACUGAGCCUUCAA. kobs=0.27
(FJ1), 0.09 (FJ8), 0.10 (FJC9) h1.
Figure 3. a) Alkaline hydrolysis and RNaseT1 digestion pattern of
reference RNA and FJ1-labeling product confirm the labeling site at
A10 (in 5’-fluorescein-GACAUACUGAGCCUUCAAAUA). b) Debranch-
ing assay with recombinant Dbr1 comparing FJ1 product (top) and
FH14 product (bottom). Time points are 0, 15, 30, and 60 min.
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recombinant Dbr1 enzyme,[10] the half-life was 4–8-fold
increased (Figure 3b).
RNA labeling with biotin by FJ ribozymes may serve for
enrichment of specific RNAs by affinity pulldown, and
biotinylated RNA could be stained indirectly with fluores-
cently labeled streptavidin or anti-biotin antibodies.[19] How-
ever, direct fluorescent labeling with small organic fluoro-
phores would be significantly preferred for fluorescence
spectroscopy or RNA imaging. In this respect, fluorescent
tenofovir analogues or derivatives with bioorthogonal func-
tional groups for conjugation of fluorophores by established
techniques are desirable as ribozyme substrates. Therefore,
the respective N6-hexynyl and N6-azidohexyl-modified teno-
fovir diphosphates were synthesized and used for the attach-
ment of fluorescein or Cy5 fluorophores through Cu-cata-
lyzed azide–alkyne cycloaddition (Scheme S2). Unmodified
tenofovir diphosphate (Ten-DP) was tested as a reference.[20]
Gratifyingly, all three FJ ribozymes tolerated various modi-
fications at the N6 position of the adenine heterocycle and
produced good yields of phosphonate-labeled RNA (Figure 4,
Figure S7). FJC9 was the slowest variant, but it also yielded
circa 80% labeled product after overnight incubation. The
fluorescent substrates FAM-Ten-DP and Cy5-Ten-DP
(Scheme S2) were tested with FJ1 and FJC9, and resulted in
40–60% fluorescently labeled RNA after 22 h.
Next, the RNA substrate scope of the tenofovir trans-
ferase ribozymes was investigated. Transition and transver-
sion mutations were introduced in the parent RNA target,
and compensatory mutations in the ribozyme binding arms to
maintain Watson–Crick base pairing, in order to explore the
potential for general and broad applications of FJ ribozymes.
FJC9 turned out as a versatile ribozyme that tolerated all
tested sequence variants, including six variants of the original
GAG sequence context, in which the G nucleotides were
individually changed to each of the other three nucleotides
(Figure 4b and Figure S8). In contrast, the FJ1 and FJ8
ribozymes were less tolerant to mutations, since neither of the
fully transition- or transversion-mutated substrates was
accepted. Stepwise expansion of the parent sequence
beyond the GAG motif determined the substrate sequence
requirement for FJ1 as RAGCY (Figure S9). Single mis-
matches between RNA target and ribozyme binding arms
next to the labeling sites significantly reduced the labeling
efficiency, indicating little propensity for off-target labeling
(Figure S10).
Direct TTR-mediated RNA labeling was then demon-
strated with FJC9 for the 120nt long E. coli 5S rRNA by
specific attachment of FAM-tenofovir to 5S rRNA. In the
context of total cellular RNA, the only fluorescein-labeled
product was detected at the desired size (total cellular RNA
was then visualized by staining with Sybr gold, Figure 5a).
Although the sequence demand of FJ1 is a bit more
restrictive, the scope is still general enough to find multiple
possible target sites in large RNAs, as demonstrated for
labeling of E. coli 16S and 23S rRNA with Cy5-tenofovir
(Figure 5b). Six target sites were chosen according to the
preferred sequence motif (Figure S12), and the corresponding
FJ1 ribozymes produced Cy5-labeled bands at the expected
positions upon analysis by agarose gel electrophoresis and
imaging in the Cy5 channel. Moreover, the FJ1 and FH14
ribozymes are truly orthogonal ribozymes without cross
reactivity (Figure S11), which can be used in a single reaction
for installation of two different fluorophores on two different
target sites within one RNA substrate (Figure 5c). Alterna-
tively, two different RNAs can be addressed simultaneously in
a single reaction, also in the context of total cellular RNA.
This is demonstrated for labeling of 23S rRNAwith Cy5-Ten-
DP by FJ1-23S-A1572 and of 16S rRNA with FAM-ATP by
FH14-16S-A412 (Figure 5d, and vice versa in Figure S13).
The labeling sites in 16S and 23S rRNA were confirmed by
primer extension assays with superscript reverse transcrip-
tase, which showed a clear stop signal at the expected
positions one nucleotide before the 2’-labeled target site
(Figure 5e and Figure S14).
In summary, we have established RNA-catalyzed labeling
of RNA using the antiviral nucleoside analogue tenofovir as
scaffold for bioorthogonal ribozyme substrates. This work
also demonstrates the reliability of the nucleotide transferase
in vitro selection strategy and the design of the structured
RNA pool for addressing a predetermined nucleotide in the
target RNA for covalent labeling. Moreover, the analysis of
the enriched library by Illumina sequencing revealed addi-
tional ribozyme variants with greater generality that would
have been missed by traditional Sanger sequencing. Impor-
tantly, the resulting phosphonate linkages proved more stable
towards yeast debranching enzyme (Dbr1) compared to the
previously used natural phosphate linkages. Other chemical
modification such as thiophosphates or thiophosphonates
could further increase the half-lives.[10] In addition, it is
worthwhile to continue searching for other ribozymes that
can form bioorthogonal linkages completely resistant to
enzymatic hydrolysis. The currently available toolbox of
Figure 4. a) Structures of unmodified tenofovir diphosphate, and ana-
logues with N6-hexynyl (alkyne) and N6-azidohexyl (azide) linkers.
Yields of labeled RNA substrate sequence in trans activity assay after
8 h (blue) and 22 h (grey) with biotin-tenofovir and analogues shown;
mean of triplicates with standard error. Yields with fluorophore labeled
tenofovir analogues after 22 h. b) Labeling of mutated target RNAs
with FJC9 and biotin-tenofovir to explore RNA substrate scope of FJC9.
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orthogonal ribozymes allows the installation of FRET pairs
on a single RNA, and to address multiple different RNAs in
one experiment with different labels, simply by the corre-
sponding design of the Watson–Crick binding arms of FH and
FJ ribozymes. It is therefore expected that these ribozymes
will find applications for labeling of RNA in vitro and may be
further improved for future cellular applications.
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